^
Association details:
| Biomarker: | EGFR mutation + KRAS mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug Class: | EGFR inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma
Excerpt:
The clinical data of 36 NSCLC patients with EGFR mutation who received TKI treatment were retrospectively analyzed….All of the patients harbored actionable sensitive EGFR mutations by NGS, with the major types being 19del or 21L858R (52.78%, 19/36 and 55.56%, 20/36, respectively). The 3 most frequent accompanying somatic mutations were TP53 (12, 48.4%), KRAS (7, 19.44%) and PIK3CA (3, 8.33%)...Concomitant mutations were significantly related to lower objective response rates (43.75% vs. 80.0%; P=0.024) and poorer PFS (P<0.001).
DOI:
10.21037/tlcr-20-679
Source:
Title:
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project
Excerpt:
A total of 204 NSCLC patients with EGFR mutated tumors treated by first generation EGFR TKI with available DNAs were collected from the biomarker France cohort....This study showed that PTEN inactivating mutations, ATM alterations, IDH1 mutations and complex EGFR mutations were predictors of short PFS in patients with a stage 4 lung adenocarcinoma receiving first line EGFR TKI and that PTEN, ATM, IDH1 and KRAS mutations as well as alterations in the MAPK pathway were related to shorter OS.
DOI:
https://doi.org/10.1016/j.lungcan.2020.11.008
